James Carmichael

21.0k total citations · 9 hit papers
72 papers, 16.6k citations indexed

About

James Carmichael is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, James Carmichael has authored 72 papers receiving a total of 16.6k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 28 papers in Molecular Biology and 15 papers in Genetics. Recurrent topics in James Carmichael's work include Cancer Treatment and Pharmacology (13 papers), PARP inhibition in cancer therapy (12 papers) and BRCA gene mutations in cancer (10 papers). James Carmichael is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), PARP inhibition in cancer therapy (12 papers) and BRCA gene mutations in cancer (10 papers). James Carmichael collaborates with scholars based in United Kingdom, United States and Switzerland. James Carmichael's co-authors include William DeGraff, John D. Minna, Adi F. Gazdar, James B. Mitchell, Andrew Tutt, Michael Friedländer, Stan B. Kaye, Ursula A. Matulonis, Timothy A. Yap and Mark Wickens and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

James Carmichael

70 papers receiving 16.2k citations

Hit Papers

Evaluation of a tetrazolium-based semiautomated colorimet... 1987 2026 2000 2013 1987 2009 2010 2012 2010 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing.
    1987 3.5k citations James Carmichael, William DeGraff et al. profile →
  2. Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
    2009 2.7k citations Peter C.C. Fong, David S. Boss et al. New England Journal of Medicine profile →
  3. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
    2010 1.7k citations M. William Audeh, James Carmichael et al. The Lancet profile →
  4. Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
    2012 1.3k citations Charlie Gourley, Michael Friedländer et al. New England Journal of Medicine profile →
  5. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
    2010 1.3k citations Andrew Tutt, Mark E. Robson et al. The Lancet profile →
  6. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
    2011 850 citations James Carmichael et al. profile →
  7. Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
    2010 745 citations Peter C.C. Fong, Timothy A. Yap et al. Journal of Clinical Oncology profile →
  8. Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer
    1999 694 citations James Carmichael et al. Journal of Clinical Oncology profile →
  9. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity.
    1987 631 citations James Carmichael, William DeGraff et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James Carmichael United Kingdom 34 10.2k 8.6k 3.0k 2.6k 2.5k 72 16.6k
Stan B. Kaye United Kingdom 65 9.5k 0.9× 8.7k 1.0× 2.1k 0.7× 3.6k 1.4× 3.6k 1.5× 217 19.2k
Beth Y. Karlan United States 69 6.4k 0.6× 8.0k 0.9× 4.4k 1.5× 6.6k 2.6× 3.9k 1.6× 336 18.9k
Timothy A. Yap United States 52 8.6k 0.8× 9.0k 1.1× 1.9k 0.6× 1.2k 0.5× 3.3k 1.3× 353 16.3k
Robert L. Sutherland Australia 78 7.8k 0.8× 10.4k 1.2× 5.0k 1.7× 586 0.2× 3.8k 1.5× 236 19.2k
Bryan T. Hennessy Ireland 59 9.0k 0.9× 9.7k 1.1× 1.7k 0.6× 1.5k 0.6× 6.4k 2.6× 266 19.8k
Elizabeth A. Musgrove Australia 60 6.6k 0.6× 7.4k 0.9× 3.0k 1.0× 435 0.2× 3.2k 1.3× 144 13.6k
Andres J. Klein–Szanto United States 83 7.0k 0.7× 12.0k 1.4× 1.6k 0.5× 601 0.2× 4.9k 2.0× 383 21.3k
Thomas Helleday Sweden 68 10.2k 1.0× 17.8k 2.1× 2.2k 0.7× 628 0.2× 4.0k 1.6× 264 22.1k
Michael J. Birrer United States 83 9.5k 0.9× 13.5k 1.6× 2.4k 0.8× 7.1k 2.8× 5.1k 2.0× 434 25.4k
V. Craig Jordan United States 74 6.4k 0.6× 6.9k 0.8× 12.2k 4.1× 981 0.4× 3.4k 1.4× 349 19.4k

Countries citing papers authored by James Carmichael

Since Specialization
Citations

This map shows the geographic impact of James Carmichael's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Carmichael with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Carmichael more than expected).

Fields of papers citing papers by James Carmichael

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Carmichael. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Carmichael. The network helps show where James Carmichael may publish in the future.

Co-authorship network of co-authors of James Carmichael

This figure shows the co-authorship network connecting the top 25 collaborators of James Carmichael. A scholar is included among the top collaborators of James Carmichael based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Carmichael. James Carmichael is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dip, Ramiro, James Carmichael, G. Strehlau, et al.. (2013). Concurrent short-term use of prednisolone with cyclosporine A accelerates pruritus reduction and improvement in clinical scoring in dogs with atopic dermatitis. BMC Veterinary Research. 9(1). 173–173. 18 indexed citations
2.
3.
Horák, Jiří, Jeff White, Adrian L. Harris, et al.. (2011). The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemotherapy and Pharmacology. 68(6). 1485–1495. 25 indexed citations
4.
Fong, Peter C.C., Timothy A. Yap, David S. Boss, et al.. (2010). Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval. Journal of Clinical Oncology. 28(15). 2512–2519. 745 indexed citations breakdown →
5.
Tutt, Andrew, Mark E. Robson, Judy E. Garber, et al.. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet. 376(9737). 235–244. 1286 indexed citations breakdown →
6.
Knights, Charlotte, Lucy C. Riches, Alan Lau, et al.. (2009). Abstract #5494: Pre-clinical evaluation of single-agent activity of the PARP inhibitor olaparib (AZD2281) in homologous recombination deficient triple-negative breast cancer. Cancer Research. 69. 5494–5494. 1 indexed citations
7.
Fong, Peter C.C., David S. Boss, Timothy A. Yap, et al.. (2009). Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers. New England Journal of Medicine. 361(2). 123–134. 2698 indexed citations breakdown →
8.
Piccart, Martine, Tomasz Burzykowski, Marc Buyse, et al.. (2008). Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer. Journal of Clinical Oncology. 26(12). 1980–1986. 164 indexed citations
9.
Alberts, David S., Franco M. Muggia, James Carmichael, et al.. (2004). Efficacy and safety of liposomal anthracyclines in Phase I/II clinical trials. Seminars in Oncology. 31(6 Suppl 13). 53–90. 114 indexed citations
10.
Ruff, Paul, Bernardo L. Rapoport, Stephen Falk, et al.. (2004). Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. BMC Cancer. 4(1). 36–36. 8 indexed citations
11.
Carmichael, James & Adrian L. Harris. (2004). The cardiovascular safety of high-dose intravenous granisetron in cancer patients receiving highly emetogenic chemotherapy. Cancer Chemotherapy and Pharmacology. 53(2). 123–128. 17 indexed citations
12.
13.
Carmichael, James. (1997). Clinical Response Benefit in Patients with Advanced Pancreatic Cancer. Digestion. 58(6). 503–507. 33 indexed citations
14.
Sullivan, Francis, James Carmichael, Eli Glatstein, & James B. Mitchell. (1996). Radiation biology of lung cancer. Journal of Cellular Biochemistry. 63(S24). 152–159. 8 indexed citations
15.
Cupissol, Didier, James Carmichael, E.M. Bessell, et al.. (1993). Evaluation of the Bioequivalence of Tablet and Capsule Formulations of Granisetron in Patients Undergoing Cytotoxic Chemotherapy for Malignant Disease. Journal of Pharmaceutical Sciences. 82(12). 1281–1284. 14 indexed citations
16.
Millward, Michael, Brian M.J. Cantwell, Ernst A. Lien, James Carmichael, & Adrian L. Harris. (1992). Intermittent high-dose tamoxifen as a potential modifier of multidrug resistance. European Journal of Cancer. 28(4-5). 805–810. 47 indexed citations
17.
Carmichael, James & Ian D. Hickson. (1991). Keynote address: Mechanisms of cellular resistance to cytotoxic drugs and X-irradiation. International Journal of Radiation Oncology*Biology*Physics. 20(2). 197–202. 17 indexed citations
18.
Carmichael, James, William DeGraff, Janet Gamson, et al.. (1989). Radiation sensitivity of human lung cancer cell lines. European Journal of Cancer and Clinical Oncology. 25(3). 527–534. 116 indexed citations
19.
Harris, Adrian L., et al.. (1989). Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer. European Journal of Cancer and Clinical Oncology. 25(7). 1105–1111. 13 indexed citations
20.
Allan, Simon, M A Cornbleet, James Carmichael, S.J. Arnott, & John F. Smyth. (1986). Adult neuroblastoma report of three cases and review of the literature. Cancer. 57(12). 2419–2421. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stan B. Kaye Breakdown of academic impact, for papers by Beth Y. Karlan Breakdown of academic impact, for papers by Timothy A. Yap Breakdown of academic impact, for papers by Robert L. Sutherland Breakdown of academic impact, for papers by Bryan T. Hennessy Breakdown of academic impact, for papers by Elizabeth A. Musgrove Breakdown of academic impact, for papers by Andres J. Klein–Szanto Breakdown of academic impact, for papers by Thomas Helleday Breakdown of academic impact, for papers by Michael J. Birrer Breakdown of academic impact, for papers by V. Craig Jordan
Rankless by CCL
2026